Invention Grant
- Patent Title: Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
-
Application No.: US16843503Application Date: 2020-04-08
-
Publication No.: US11078261B2Publication Date: 2021-08-03
- Inventor: Ronald Bradley Demattos , Jirong Lu , Ying Tang
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Neelaabh Shankar
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61P25/28 ; A61K39/00
Abstract:
Antibodies to human N3pGlu Aβ, compositions comprising such N3pGlu Aβ antibodies, and methods of using such N3pGlu Aβ antibodies for the treatment of a disease characterized by deposition of Aβ including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
Public/Granted literature
- US20200262902A1 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF Public/Granted day:2020-08-20
Information query
